Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs Teradyne, Inc. (TER) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs Teradyne, Inc. — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $106.75 (market cap $8.88B), while Teradyne, Inc. trades at $339.19 (market cap $56.20B). The key difference: Teradyne, Inc. is far larger — about 6.3× Kymera Therapeutics Inc. Common Stock's market cap, and Teradyne, Inc. pays a 0.14% dividend while Kymera Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and Teradyne, Inc. for 37 Days on average.
| KYMR | TER | |
|---|---|---|
Market Cap | $8.88B | $56.20B |
Volume | 1,028,790 | 3,754,298 |
Sector | Health | Technology |
52-Week High | $127.31 | $483.84 |
52-Week Low | $55.80 | $138.09 |
Typical Hold Time | 0 Days | 37 Days |
Enterprise Value | $8.27B | $55.94B |
Dividend Yield | — | 0.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Teradyne (TER) trades at $380.29, down 0.93% on the day, with a bearish technical signal as it tests support near $378. The stock shows strong fundamentals with three consecutive quarterly EPS beats and robust profitability margins, including a 25.77% net income margin. Recent news highlights expansion in AI-driven memory test systems and a strategic partnership with GSME, positioning the company in high-growth semiconductor markets. Analyst consensus remains optimistic with a $461.50 price target and no sell ratings among 31 analysts.
The outlook for TER is positive due to strong earnings momentum and strategic positioning in AI and semiconductor testing, though elevated valuation ratios like a P/E of 49.37 pose a risk if growth slows. Key risks include competitive pressures from KLAC and COHU, cyclical semiconductor demand, and insider selling activity. Institutional interest remains strong, supporting a moderate buy recommendation for long-term investors focused on tech infrastructure growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About Teradyne, Inc.
Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Read more on TER →
